{
    "sponsor_name": "FADOI /BMS/PFIZER",
    "study_acronym": "CARAVAGGIO Study",
    "tested_imp": "Apixaban",
    "comparative_drug": "Dalteparin",
    "study_type": "Interventional",
    "interventional_study_phase": "Phase IIIb",
    "study_design": "International, multicenter, Prospective Randomized Open Blinded End-point (PROBE), active-controlled, event-driven, Phase IIIB clinical study",
    "comparison": "efficacy and safety of Apixaban to Dalteparin for treatment of venous thromboembolism in cancer patients",
    "aim_of_study": "assess whether oral apixaban is non-inferior to subcutaneous LMWH dalteparin for the treatment of newly diagnosed proximal DVT and/or PE in patients with cancer",
    "target_disease": "VTE (DVT/PE) in cancer patients",
    "randomization_ratio": "1:1",
    "randomization_blocks": "permuted blocks of four",
    "randomization_stratification": [
        "symptomatic vs. unsuspected VTE",
        "active cancer vs. history of cancer"
    ],
    "apixaban_dose_initial": "10 mg bid for 7 days",
    "apixaban_dose_maintenance": "5 mg bid for six months",
    "dalteparin_dose_initial": "200 IU/kg SC o.i.d for 1 month",
    "dalteparin_dose_maintenance": "150 IU/kg o.i.d. for 5 months",
    "dalteparin_max_daily_dose": "18,000 IU",
    "apixaban_form": "film-coated tablets",
    "dalteparin_form": "single-use pre-filled syringes",
    "visit_schedule": [
        "enrollment",
        "4 weeks",
        "3 months",
        "6 months",
        "end of study treatment",
        "7 months from randomization"
    ],
    "primary_efficacy_outcome": "objectively confirmed recurrent VTE during the study period",
    "secondary_efficacy_outcomes": [
        "individual components of primary efficacy outcome",
        "symptomatic recurrence of VTE",
        "all cause death",
        "primary efficacy outcome plus major bleeding",
        "primary efficacy outcome plus major bleeding plus all cause death",
        "primary efficacy outcome plus all cause death",
        "any major cardiovascular event (including acute myocardial infarction or ischemic stroke)",
        "all venous thromboembolic events (including splanchnic vein thrombosis and cerebral vein thrombosis)",
        "Quality of life according to Anti-Clot Treatment Scale (ACTS)"
    ],
    "primary_safety_outcome": "major bleeding as per ISTH guidelines",
    "major_bleeding_definition": [
        "decrease in hemoglobin of 2 g/dl (1.2 mmol/L) or more",
        "transfusion of 2 or more units of packed red blood cells",
        "bleeding in at least one critical site",
        "bleeding that is fatal",
        "bleeding that necessitates acute surgical intervention"
    ],
    "secondary_safety_outcomes": [
        "clinically relevant non-major bleeding",
        "clinically relevant bleeding (composite of major and non-major)",
        "permanent early discontinuation of study drug due to safety reasons"
    ],
    "maximum_sample_size_per_arm": "<600",
    "inclusion_criteria": [
        "age > 18 years",
        "both genders",
        "signed informed consent",
        "newly diagnosed, objectively confirmed symptomatic or unsuspected proximal lower-limb DVT or symptomatic PE or unsuspected PE in segmental or more proximal pulmonary artery",
        "any type of cancer except basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, acute leukemia",
        "active cancer or cancer diagnosed within 2 years before study inclusion"
    ],
    "exclusion_criteria": [
        "age <18 years",
        "ECOG Performance Status III or IV",
        "life expectancy <6 months",
        "therapeutic doses of LMWH, fondaparinux, or UFH >72 hours before randomization",
        "3 or more doses of vitamin K antagonist before randomization",
        "thrombectomy, vena cava filter insertion, or thrombolysis to manage index episode",
        "indication for anticoagulant treatment for disease other than index VTE episode",
        "concomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein",
        "concomitant thienopyridine therapy or aspirin >165 mg daily or dual antiplatelet therapy",
        "active bleeding or high risk of bleeding contraindicating anticoagulant treatment",
        "recent (last 1 month) brain, spinal, or ophthalmic surgery",
        "hemoglobin <8 g/dL (5.0 mmol/L)",
        "platelet count <75x10^9/L",
        "history of heparin-induced thrombocytopenia",
        "creatinine clearance <30 ml/min (Cockcroft Gault)",
        "acute hepatitis, chronic active hepatitis, liver cirrhosis",
        "alanine aminotransferase >3x upper limit of normal",
        "bilirubin >2x upper limit of normal",
        "uncontrolled hypertension (systolic BP >180 mm Hg or diastolic BP >100 mm Hg)",
        "bacterial endocarditis",
        "hypersensitivity to study drugs or excipients",
        "participation in other pharmaco therapeutic program with experimental therapy affecting coagulation",
        "WOCBP not practicing highly effective contraception during trial and one month beyond",
        "pregnancy or breastfeeding",
        "any condition judged by investigator to increase risk of harm"
    ]
}